Cardio-Oncology and Breast Cancer Therapies

Curr Treat Options Oncol. 2025 May;26(5):385-397. doi: 10.1007/s11864-025-01311-x. Epub 2025 Apr 21.

Abstract

Assessing cardiac risk prior to initiating breast cancer treatment, monitoring cardiac function during treatment, and implementing appropriate follow-up strategies are essential components of managing cardiotoxicity in breast cancer patients. A comprehensive cardiovascular evaluation should be conducted before treatment, including a detailed medical history, physical examination, and baseline cardiac imaging. Risk stratification tools can aid in determining the individual patient's risk profile. Close monitoring of cardiac function, including regular assessment of left ventricular ejection fraction (LVEF) and monitoring for signs and symptoms of cardiac dysfunction, is crucial during treatment. Prompt action should be taken if an adverse cardiovascular event is detected, including considering discontinuing or modifying the treatment regimen. Appropriate follow-up care is essential to monitor for long-term cardiac effects and optimize cardiovascular health in breast cancer survivors. Regular cardiovascular assessments, lifestyle modifications, and collaboration between healthcare professionals are important in managing cardiotoxicity effectively.

Keywords: Breast cancer; Cardio-oncology; Cardiotoxicity.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents* / adverse effects
  • Antineoplastic Agents* / therapeutic use
  • Breast Neoplasms* / complications
  • Breast Neoplasms* / drug therapy
  • Breast Neoplasms* / therapy
  • Cardio-Oncology
  • Cardiotoxicity / diagnosis
  • Cardiotoxicity / etiology
  • Cardiovascular Diseases* / diagnosis
  • Cardiovascular Diseases* / etiology
  • Disease Management
  • Female
  • Humans
  • Risk Factors

Substances

  • Antineoplastic Agents